Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2018—Quidel received 510(k) clearance from the FDA to market its Solana Bordetella Complete Assay, a molecular diagnostic assay for use with the Solana instrument for the qualitative detection and differentiation of Bordetella pertussis and Bordetella parapertussis nucleic acids isolated from nasopharyngeal swab specimens.
September 2018—NeuMoDx Molecular announced it has received FDA 510(k) clearance for its NeuMoDx 288 Molecular System and NeuMoDx GBS Assay. The fully automated NeuMoDx 288 is a scalable platform that integrates the diagnostic process, from extraction to detection, in approximately one hour. The analyzer can load up to 288 patient samples in a continuous random-access mode and features a walkaway time of more than six hours.
August 2018—Binding Site’s Immunologicals Group has added infectious and contagious disease state sera and plasma products to its line of products. The human-based serum/plasma biological materials cover a variety of infectious and contagious disease state conditions, including Epstein-Barr virus, influenza, measles, mumps, TORCH, and West Nile. Evaluation samples are available and all materials come in bulk formats for use in the manufacturing of calibration and quality control materials. The company offers comprehensive data on analyte positives and negatives along with a certificate of analysis. In a separate release, the Immunologicals Group announced it has expanded its antibody and antigen product offerings for human coagulation and complement applications.
August 2018—Aquaro Histology announced the launch of the Aquaro Wishbone blade-handling tool. The handheld tool allows histologists to remove and dispose of blades, as well as insert and align them, without having to touch the blade.
August 2018—Qiagen launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents to enable accurate microbial community profiling from complex microbiome samples. The UCP Multiplex PCR Kit is a standalone product as well as a component of the QIAseq 16S/ITS Panels.
August 2018—Natera announced a research collaboration with the Institut Jules Bordet, in Brussels, using the company’s Signatera research-use-only circulating tumor DNA assay to evaluate molecular response and minimal residual disease in women with early stage breast cancer.
August 2018—Luxembourg-based Advanced Biological Laboratories has signed a definitive agreement to acquire CDL Pharma. CDL Pharma, headquartered in France, provides biological sample management solutions in clinical research for pharmaceutical laboratories, contact research organizations, biotechnology companies, and others.
August 2018—Hologic has obtained approval from Health Canada for its Panther Fusion system and Panther Fusion assays for respiratory virus infections. The Panther Fusion module adds the capacity to run PCR assays in addition to tests based on transcription-mediated amplification, the proprietary Hologic chemistry that powers the company’s Aptima brand.
August 2018—Agena Bioscience has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics, an independent medical laboratories provider headquartered in Hangzhou, China.
August 2018—Array BioPharma announced that the FDA has approved Braftovi (encorafenib) capsules in combination with Mektovi (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation, as detected by an FDA-approved test.
